Pickkers P, Hughes A D, Russel F G, Thien T, Smits P
Division of General Internal Medicine, Department of Medicine, and Department of Pharmacology, University Hospital Nijmegen, Nijmegen, Netherlands.
Hypertension. 1998 Dec;32(6):1071-6. doi: 10.1161/01.hyp.32.6.1071.
-Hydrochlorothiazide and indapamide are thought to exert their hypotensive efficacy through a combined vasodilator and diuretic effect, but in vivo evidence for a direct vascular effect is lacking. The presence and mechanism of a direct vascular action of hydrochlorothiazide in vivo in humans were examined and compared with those of the thiazide-like drug indapamide. Forearm vasodilator responses to infusion of placebo and increasing doses of hydrochlorothiazide (8, 25, and 75 microg. min-1. dL-1) into the brachial artery were recorded by venous occlusion plethysmography. Dose-response curves were repeated after local tetraethylammonium (TEA) administration to determine the role of potassium channel activation and, in patients with the Gitelman syndrome, to determine the role of the thiazide-sensitive Na-Cl cotransporter in the vasodilator effect of hydrochlorothiazide. Vascular effects of hydrochlorothiazide were compared with those of indapamide in both normotensive (mean arterial pressure, 85+/-7 mm Hg) and hypertensive (mean arterial pressure, 124+/-16 mm Hg) subjects. At the highest infusion rate, local plasma concentrations of hydrochlorothiazide averaged 11.0+/-1.6 microg/mL, and those of indapamide averaged 7. 2+/-1.5 microg/mL. In contrast to indapamide, hydrochlorothiazide showed a direct vascular effect (maximal vasodilation, 55+/-14%; P=0. 013), which was inhibited by TEA (maximal vasodilation after TEA, 13+/-10%; P=0.02). The response was not dependent on blood pressure and was similar in patients with Gitelman syndrome, indicating that absence of the Na-Cl cotransporter does not alter the vasodilatory effect of hydrochlorothiazide. The vasodilator effect of hydrochlorothiazide in the human forearm is small and only occurs at high concentrations. The mechanism of action is not mediated by inhibition of vascular Na-Cl cotransport but involves vascular potassium channel activation. In contrast, indapamide does not exert any direct vasoactivity in the forearm vascular bed.
氢氯噻嗪和吲达帕胺被认为通过血管舒张和利尿的联合作用发挥其降压功效,但缺乏体内直接血管作用的证据。本研究检测了氢氯噻嗪在人体体内的直接血管作用及其机制,并与噻嗪类药物吲达帕胺进行了比较。通过静脉阻断体积描记法记录前臂对安慰剂输注以及向肱动脉内递增剂量氢氯噻嗪(8、25和75微克·分钟⁻¹·分升⁻¹)的血管舒张反应。在局部给予四乙铵(TEA)后重复剂量反应曲线,以确定钾通道激活的作用,并在患有吉特林综合征的患者中确定噻嗪敏感的钠氯共转运体在氢氯噻嗪血管舒张作用中的作用。在血压正常(平均动脉压,85±7毫米汞柱)和高血压(平均动脉压,124±16毫米汞柱)受试者中比较了氢氯噻嗪和吲达帕胺的血管作用。在最高输注速率下,氢氯噻嗪的局部血浆浓度平均为11.0±1.6微克/毫升,吲达帕胺的局部血浆浓度平均为7.2±1.5微克/毫升。与吲达帕胺不同,氢氯噻嗪显示出直接血管作用(最大血管舒张,55±14%;P=0.013),该作用被TEA抑制(TEA后最大血管舒张,13±10%;P=0.02)。该反应不依赖于血压,在吉特林综合征患者中相似,表明钠氯共转运体的缺失不会改变氢氯噻嗪的血管舒张作用。氢氯噻嗪在人前臂中的血管舒张作用较小,且仅在高浓度时发生。其作用机制不是通过抑制血管钠氯共转运介导的,而是涉及血管钾通道激活。相比之下,吲达帕胺在前臂血管床中不发挥任何直接血管活性作用。